AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 181 min read$BRKR

Pusch Wolfgang sold $198K of BRKR

Pusch Wolfgang (President BMID Group) sold 3,473 shares of BRUKER CORP (BRKR) at $56.90 ($0.20M total) on 2026-08-17.

Original reporting
SEC EDGAR · Pusch Wolfgang
Published Aug 18, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BRKR
Neutral
medium confidence
Mentioned
$BRKR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BRKRNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by an officer (President, BMID Group) on 2026-08-17, filed on 2026-08-18.

02

Market read

Traders may note insider selling, but the disclosed dollar value is small and there is no accompanying fundamental catalyst.

03

What to watch

The filing does not indicate a 10b5-1 plan, but it also provides no context on motivations or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Bruker Corp (BRKR).

Company-level read

Ticker impact

$BRKRNeutralMedium confidence
Context

Form 4 shows Pusch Wolfgang sold 3,473 BRKR shares in an open-market sale for about $197.6K.

Expected impact

Likely minimal near-term impact; any effect is more about signaling than new fundamentals.

Evidence & confidence

The filing is a disclosed transaction size of roughly $0.2M and lacks any accompanying corporate event, guidance, or operational change.

Market effects

Sector

No clear sector read-through from a single small insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations.

Key entities

  • issuer
    BRUKER CORP

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Pusch Wolfgang

    President, BMID Group, reported an open-market sale of BRKR shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BRKR insider trading history →

Related articles

OCT 14
$BRKRMed

J.P. Morgan Downgrades Bruker Corporation (BRKR) to Neutral Amid

J.P. Morgan downgraded Bruker Corporation (BRKR) to Neutral with a $70 price target, citing concerns about its Academia & Government segment and uncertain revenue growth. Bruker's P/S ratio is 2.45x, below its historical median and industry average. The company has a GF Score of 84/100, with strengths in valuation and momentum, but faces insider selling and mixed institutional interest.

gurufocus.com2 min
OCT 14
$BRKRMed

Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage

J.P. Morgan downgraded Bruker (BRKR) to Neutral and Sotera Health (SHC) to Underweight, citing uncertainty in their respective markets. Analyst Casey Woodring maintained a $70 price target for Bruker but expressed concerns about its exposure to lagging segments. For Sotera, Woodring lowered the price target to $17 from $18, citing underperformance tied to its medtech client base.

tradingview.com2 min
SEP 16
$BRKRMed

BRKR Stock Slides As Fusion Deal Collides With UBS Reality Check

Bruker Corporation (BRKR) stock rose 7.62% after strong earnings and guidance. The company's BEST unit partnered with Luvata for superconducting wire production, tying it to fusion and high-field magnet projects. UBS raised its price target to $65 but maintained a Neutral rating, citing mixed growth prospects. BRKR's revenue is $3.44B, but it reported a net loss of $52M and negative free cash flow.

stockstotrade.com3 min
SEP 16
$BRKRMed

BRKR Stock Pulls Back As Fusion Bet And UBS Target Collide

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.

timothysykes.com3 min